Nuclea Biotechnologies is Therapeutic Devices in United States that focus on prostate cancer business. Founded in 2005. They cover business area such as developer, clinical diagnostic test, diagnostic development, cancer, a suite, highly sensitive, specific and selective proteomic test, proprietary technology, mass spec testing capability, that fuel growth, metabolic disease, doctor, early detection, monitoring, diabetes, medicine.
2005
( 21 years old in 2026 )
Prostate Cancer
-
46-48 Elm Street
Pittsfield, MA 01201
United States
Private
developerclinical diagnostic testdiagnostic developmentcancera suitehighly sensitive, specific and selective proteomic testproprietary technologymass spec testing capabilitythat fuel growthmetabolic diseasedoctorearly detectionmonitoringdiabetesmedicine
* We use standard office opening hours in near Nuclea Biotechnologies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Nuclea Biotechnologies is Therapeutic Devices business from United States that founded in 2005 (21 years old in 2026), Nuclea Biotechnologies business is focusing on Prostate Cancer.
Nuclea Biotechnologies headquarter office and corporate office address is located in 46-48 Elm Street Pittsfield, MA 01201 United States.
Nuclea Biotechnologies was founded in United States.
In 2026, Nuclea Biotechnologies is currently focus on prostate cancer sector.
Above is snippet of Google Trends for "prostate cancer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Nuclea Biotechnologies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
